IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: IL-6 was higher in CML patients and was elevated during the transformation phase of CML (Panteli et al., 2005), while blocking IL-6 signaling could delay CML development in mouse model (Reynaud et al., 2011).